Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus-Reference-Cited by-同舟云学术

Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lam Angela M.¹,Espiritu Christine¹,Vogel Robert¹,Ren Suping¹,Lau Vincent¹,Kelly Mollie¹,Kuduk Scott D.¹,Hartman George D.¹,Flores Osvaldo A.¹,Klumpp Klaus¹

Affiliation:

1. Novira Therapeutics, Inc., Spring House, Pennsylvania, USA

Abstract

NVR 3-778 is the first capsid assembly modulator (CAM) that has demonstrated antiviral activity in hepatitis B virus (HBV)-infected patients. NVR 3-778 inhibited the generation of infectious HBV DNA-containing virus particles with a mean antiviral 50% effective concentration (EC 50 ) of 0.40 µM in HepG2.2.15 cells.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01734-18

Reference27 articles.

1. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

3. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

4. AASLD guidelines for treatment of chronic hepatitis B

5. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection;European Journal of Pharmaceutical Sciences;2024-09

3. Hepatitis B: Model Systems and Therapeutic Approaches;Journal of Immunology Research;2024-05-07

4. A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression;Antiviral Research;2024-01

5. SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection;Antiviral Research;2023-12